Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,864 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: SARS CoV 2 Infection
Interventions: Sotrovimab; Drug
Lead sponsor: Sophia Koo, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Childhood Apraxia of Speech
Interventions: Dynamic Temporal and Tactile Cueing - Connect (DTTC-Connect); Behavioral
Lead sponsor: New York University; Other
Eligibility: 3 Years to 12 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Hempstead, New York • New York, New York

Conditions: Healthy Participants
Interventions: TAK-906 Maleate, Itraconazole; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Diabetes Mellitus, Type 2
Interventions: Glimepiride, Placebo, Linagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 16
States / cities: Chula Vista, California • Pembroke Pines, Florida • Decatur, Georgia + 11 more

Conditions: Diabetes, Asthma, Chronic Obstructive Pulmonary Disease, Hypertension, Anxiety, Atrial Fibrillation, Congestive Heart Failure, Depression, Bipolar Disorder, Schizophrenia
Interventions: High-Touch, High-Tech, Optimal Discharge Planning; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 21 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Alcohol Use Disorder, Insomnia
Interventions: Daridorexant, Placebo, Brief Counseling, MEMS and Medication Accounting, Contingency Management for Medication Adherence; Drug · Behavioral · Device
Lead sponsor: Sterling McPherson; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Healthy
Interventions: LY3502970, Placebo, Atorvastatin, Simvastatin, Midazolam; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Advanced Liver Cancer
Interventions: ABSK-011; Drug
Lead sponsor: Abbisko Therapeutics Co, Ltd; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 6
States / cities: Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 3 more

Conditions: Aphasia, Apraxia of Speech, Stroke
Interventions: Sound Production Treatment - Blocked, Sound Production Treatment - Random; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Volunteers
Interventions: Vonoprazan ODT-1 or ODT-2 without Water, Vonoprazan ODT-1 or ODT-2 with Water, Vonoprazan (Reference); Drug
Lead sponsor: Phathom Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: CNS Lymphoma, CNS Brain Cancer, Non-Hodgkin's Lymphoma
Interventions: Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 72 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2023
U.S. locations: 3
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York

Conditions: Constipation
Interventions: naloxegol; Drug
Lead sponsor: Joseph Ma; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Stress Disorders, Post-Traumatic
Interventions: EEG-based personalized TMS; Device
Lead sponsor: Wave Neuroscience; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Opioid-use Disorder
Interventions: Treatment Navigation (Intervention), Control; Behavioral · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: Auburn, Washington • Burien, Washington • Federal Way, Washington + 2 more

Conditions: Diabetes Mellitus, Kidney Transplant; Complications
Interventions: Free style libre-2; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Stress Disorders, Post-Traumatic, Opioid Use Disorder
Interventions: Written Exposure Therapy - Integrated; Behavioral
Lead sponsor: Jesse McCann; Other
Eligibility: 18 Years to 100 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Bipolar I Disorder
Interventions: Lithium treatment in combination with a SGA (Second Generation Antipsychotic), Placebo/Adjunctive SGA treatment; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 12 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Healthy Volunteer
Interventions: Ro542-4802/F03 (Reference), Ro542-4802/F07 (Test), Ro542-4802/F08 (Test), Ro542-4802/F14 (Test); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Andersen-Tawil Syndrome
Interventions: Potassium, Acetazolamide; Dietary Supplement · Drug
Lead sponsor: University of Rochester; Other
Eligibility: 10 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, T-Cell Prolymphocytic Leukemia
Interventions: Letermovir; Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Bladder Cancer, Urothelial Carcinoma, Urinary Bladder Neoplasm, Urinary Bladder Cancer, Urogenital Neoplasms, Urologic Neoplasms, Urologic Cancer, Malignant Tumor of the Urinary Bladder, Cancer of the Bladder
Interventions: NanoDoce (direct injection), NanoDoce (intravesical instillation) - Visit 2 Instillation, Institutional Standard of Care, NanoDoce (intravesical instillation) - Induction and Maintenance Instillations; Drug · Other
Lead sponsor: NanOlogy, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Phoenix, Arizona • Baltimore, Maryland • New York, New York + 2 more

Conditions: Type 2 Diabetes Mellitus, Overweight
Interventions: TANTALUS(TM) System; Device
Lead sponsor: MetaCure (USA), Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 10
States / cities: La Jolla / San Diego, California • Los Angeles, California • Denver, Colorado + 6 more

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Standard of care; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 78
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more

Conditions: Type1diabetes
Interventions: BKR-017; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 20 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals

Motor-based Intervention for Childhood Apraxia of Speech: DTTC-Connect

A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants

Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

Integrated Care (IC) Models for Patient-Centered Outcomes

Daridorexant for People With Insomnia and Alcohol Use Disorder Study

A Study of LY3502970 in Healthy Participants

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

Treatments of Acquired Apraxia of Speech

A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants

Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma

Naloxegol in Cancer Opioid-Induced Constipation

EEG Personalized Transcranial Magnetic Stimulation (eTMS) for Post-Traumatic Stress Disorder

Treatment Navigation for Opioid Use Disorder

Continuous Glucose Monitoring (CGM) in Kidney-Transplanted Adults

New Beginnings Following Trauma

Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania

A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers

Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

The TANTALUS® II System for the Treatment of Type 2 Diabetes: A Randomized Study

Open Label Study of Long Term Evaluation Against LDL-C Trial

Butyrate Adjuvant Therapy for Type 1 Diabetes